All data are based on the daily closing price as of April 28, 2025
k

KYORIN Pharmaceutical

4569.TSE
10.33 USD
0.02
+0.19%

Overview

Last close
10.33 usd
Market cap
593.43M usd
52 week high
12.35 usd
52 week low
8.88 usd
Target price
9.06 usd

Valuation

P/E
18.0828
Forward P/E
N/A
Price/Sales
0.7157
Price/Book Value
0.6526
Enterprise Value
661.96M usd
EV/Revenue
0.7932
EV/EBITDA
8.745

Key financials

Revenue TTM
847.22M usd
Gross Profit TTM
360.81M usd
EBITDA TTM
64.63M usd
Earnings per Share
0.57 usd
Dividend
0.36 usd
Total assets
1.22B usd
Net debt
112.43M usd

About

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
  • Symbol
    4569.TSE
  • Exchange
    TSE
  • Isin
    JP3247090008
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Yutaka Ogihara
  • Headquarter
    Tokyo
  • Web site
    https://www.kyorin-pharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top